APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Rabies Immunoglobulin (IM)

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.

In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)

Selected research

Market Structure

Global Human Rabies Immunoglobulin (IM) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025190 pages

Choose your research edition.

Industry ResearchHuman Rabies Immunoglobulin (IM) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Rabies Immunoglobulin (IM) Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Human Rabies Immunoglobulin (IM) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Rabies Immunoglobulin (IM) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Rabies Immunoglobulin (IM) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.

In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)

Read the full market overview

Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.

North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.

In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.

This report provides an overview of the global Human Rabies Immunoglobulin (IM) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Rabies Immunoglobulin (IM) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Rabies Immunoglobulin (IM) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Rabies Immunoglobulin (IM) market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Rabies Immunoglobulin (IM) Segment by Company

CSL Behring

Grifols

Sanofi

Sichuan Yuanda Shuyang

CNBG

Kamada

CBPO

Shuanglin Bio

Weiguang Bio

Shanghai RAAS

Bharat Serum

VINS

Human Rabies Immunoglobulin (IM) Segment by Type

ERIG

HRIG

Human Rabies Immunoglobulin (IM) Segment by Application

Category II Exposure

Category III Exposure

Human Rabies Immunoglobulin (IM) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Rabies Immunoglobulin (IM) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Rabies Immunoglobulin (IM) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Rabies Immunoglobulin (IM).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Rabies Immunoglobulin (IM) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Human Rabies Immunoglobulin (IM) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Human Rabies Immunoglobulin (IM) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Human Rabies Immunoglobulin (IM) Industry Trends Table 2. Human Rabies Immunoglobulin (IM) Industry Drivers Table 3. Human Rabies Immunoglobulin (IM) Industry Opportunities and Challenges Table 4. Human Rabies Immunoglobulin (IM) Industry Restraints Table 5. Global Human Rabies Immunoglobulin (IM) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Human Rabies Immunoglobulin (IM) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Manufacturers Table 9. Global Human Rabies Immunoglobulin (IM) Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Human Rabies Immunoglobulin (IM) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Human Rabies Immunoglobulin (IM) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Human Rabies Immunoglobulin (IM) Manufacturers, Product Type & Application Table 13. Global Human Rabies Immunoglobulin (IM) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Rabies Immunoglobulin (IM) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ERIG Table 17. Major Manufacturers of HRIG Table 18. Global Human Rabies Immunoglobulin (IM) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Human Rabies Immunoglobulin (IM) Sales by Type (2021-2026) & (K Units) Table 20. Global Human Rabies Immunoglobulin (IM) Sales by Type (2027-2032) & (K Units) Table 21. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2021-2026) Table 22. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2027-2032) Table 23. Global Human Rabies Immunoglobulin (IM) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Human Rabies Immunoglobulin (IM) Revenue by Type (2021-2026) & (K Units) Table 25. Global Human Rabies Immunoglobulin (IM) Revenue by Type (2027-2032) & (K Units) Table 26. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2021-2026) Table 27. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Category II Exposure Table 29. Major Manufacturers of Category III Exposure Table 30. Global Human Rabies Immunoglobulin (IM) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Human Rabies Immunoglobulin (IM) Sales by Application (2021-2026) & (K Units) Table 32. Global Human Rabies Immunoglobulin (IM) Sales by Application (2027-2032) & (K Units) Table 33. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2021-2026) Table 34. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2027-2032) Table 35. Global Human Rabies Immunoglobulin (IM) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Human Rabies Immunoglobulin (IM) Revenue by Application (2021-2026) & (K Units) Table 37. Global Human Rabies Immunoglobulin (IM) Revenue by Application (2027-2032) & (K Units) Table 38. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2021-2026) Table 39. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2027-2032) Table 40. Global Human Rabies Immunoglobulin (IM) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Human Rabies Immunoglobulin (IM) Sales by Region (2021-2026) & (K Units) Table 42. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Region (2021-2026) Table 43. Global Human Rabies Immunoglobulin (IM) Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Human Rabies Immunoglobulin (IM) Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Human Rabies Immunoglobulin (IM) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Human Rabies Immunoglobulin (IM) Sales by Country (2021-2026) & (K Units) Table 47. North America Human Rabies Immunoglobulin (IM) Sales by Country (2027-2032) & (K Units) Table 48. Europe Human Rabies Immunoglobulin (IM) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Human Rabies Immunoglobulin (IM) Sales by Country (2021-2026) & (K Units) Table 50. Europe Human Rabies Immunoglobulin (IM) Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Human Rabies Immunoglobulin (IM) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2027-2032) & (K Units) Table 57. Global Human Rabies Immunoglobulin (IM) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Human Rabies Immunoglobulin (IM) Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Human Rabies Immunoglobulin (IM) Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Region (2021-2026) Table 61. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Region (2027-2032) Table 62. CSL Behring Company Information Table 63. CSL Behring Business Overview Table 64. CSL Behring Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio Table 66. CSL Behring Recent Development Table 67. Grifols Company Information Table 68. Grifols Business Overview Table 69. Grifols Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Grifols Human Rabies Immunoglobulin (IM) Product Portfolio Table 71. Grifols Recent Development Table 72. Sanofi Company Information Table 73. Sanofi Business Overview Table 74. Sanofi Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio Table 76. Sanofi Recent Development Table 77. Sichuan Yuanda Shuyang Company Information Table 78. Sichuan Yuanda Shuyang Business Overview Table 79. Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio Table 81. Sichuan Yuanda Shuyang Recent Development Table 82. CNBG Company Information Table 83. CNBG Business Overview Table 84. CNBG Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. CNBG Human Rabies Immunoglobulin (IM) Product Portfolio Table 86. CNBG Recent Development Table 87. Kamada Company Information Table 88. Kamada Business Overview Table 89. Kamada Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Kamada Human Rabies Immunoglobulin (IM) Product Portfolio Table 91. Kamada Recent Development Table 92. CBPO Company Information Table 93. CBPO Business Overview Table 94. CBPO Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. CBPO Human Rabies Immunoglobulin (IM) Product Portfolio Table 96. CBPO Recent Development Table 97. Shuanglin Bio Company Information Table 98. Shuanglin Bio Business Overview Table 99. Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio Table 101. Shuanglin Bio Recent Development Table 102. Weiguang Bio Company Information Table 103. Weiguang Bio Business Overview Table 104. Weiguang Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio Table 106. Weiguang Bio Recent Development Table 107. Shanghai RAAS Company Information Table 108. Shanghai RAAS Business Overview Table 109. Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio Table 111. Shanghai RAAS Recent Development Table 112. Bharat Serum Company Information Table 113. Bharat Serum Business Overview Table 114. Bharat Serum Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio Table 116. Bharat Serum Recent Development Table 117. VINS Company Information Table 118. VINS Business Overview Table 119. VINS Human Rabies Immunoglobulin (IM) Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. VINS Human Rabies Immunoglobulin (IM) Product Portfolio Table 121. VINS Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Human Rabies Immunoglobulin (IM) Distributors List Table 125. Human Rabies Immunoglobulin (IM) Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Human Rabies Immunoglobulin (IM) Product Image Figure 2. Global Human Rabies Immunoglobulin (IM) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Rabies Immunoglobulin (IM) Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Rabies Immunoglobulin (IM) Sales (2021-2032) & (K Units) Figure 5. Global Human Rabies Immunoglobulin (IM) Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Human Rabies Immunoglobulin (IM) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ERIG Image Figure 9. HRIG Image Figure 10. Global Human Rabies Immunoglobulin (IM) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Human Rabies Immunoglobulin (IM) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2021-2032) Figure 13. Global Human Rabies Immunoglobulin (IM) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Human Rabies Immunoglobulin (IM) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2021-2032) Figure 16. Category II Exposure Image Figure 17. Category III Exposure Image Figure 18. Global Human Rabies Immunoglobulin (IM) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Human Rabies Immunoglobulin (IM) Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2021-2032) Figure 21. Global Human Rabies Immunoglobulin (IM) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Human Rabies Immunoglobulin (IM) Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2021-2032) Figure 24. North America Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021-2032) Figure 26. U.S. Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021-2032) Figure 31. Germany Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021-2032) Figure 38. China Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021-2032) Figure 46. Brazil Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Human Rabies Immunoglobulin (IM) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Human Rabies Immunoglobulin (IM) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Human Rabies Immunoglobulin (IM) Revenue (2021-2032) & (US$ Million) Figure 57. North America Human Rabies Immunoglobulin (IM) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Human Rabies Immunoglobulin (IM) Revenue (2021-2032) & (US$ Million) Figure 59. Europe Human Rabies Immunoglobulin (IM) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Human Rabies Immunoglobulin (IM) Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Human Rabies Immunoglobulin (IM) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Human Rabies Immunoglobulin (IM) Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Human Rabies Immunoglobulin (IM) Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • ERIG
  • HRIG
Applications
  • Category II Exposure
  • Category III Exposure
Companies covered
  • CSL Behring
  • Grifols
  • Sanofi
  • Sichuan Yuanda Shuyang
  • CNBG
  • Kamada
  • CBPO
  • Shuanglin Bio
  • Weiguang Bio
  • Shanghai RAAS
  • Bharat Serum
  • VINS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Rabies Immunoglobulin (IM) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Rabies Immunoglobulin (IM) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Human Rabies Immunoglobulin (IM) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Human Rabies Immunoglobulin (IM) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Human Rabies Immunoglobulin (IM) Market Dynamics
  1. 2.1 Human Rabies Immunoglobulin (IM) Industry Trends
  2. 2.2 Human Rabies Immunoglobulin (IM) Industry Drivers
  3. 2.3 Human Rabies Immunoglobulin (IM) Industry Opportunities and Challenges
  4. 2.4 Human Rabies Immunoglobulin (IM) Industry Restraints
3 Human Rabies Immunoglobulin (IM) Market by Manufacturers
  1. 3.1 Global Human Rabies Immunoglobulin (IM) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Human Rabies Immunoglobulin (IM) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Human Rabies Immunoglobulin (IM) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Human Rabies Immunoglobulin (IM) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Human Rabies Immunoglobulin (IM) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Human Rabies Immunoglobulin (IM) Manufacturers, Product Type & Application
  7. 3.7 Global Human Rabies Immunoglobulin (IM) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Human Rabies Immunoglobulin (IM) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Human Rabies Immunoglobulin (IM) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Human Rabies Immunoglobulin (IM) Tier 1, Tier 2, and Tier 3
4 Human Rabies Immunoglobulin (IM) Market by Type
  1. 4.1 Human Rabies Immunoglobulin (IM) Type Introduction
  2. 4.1.1 ERIG
  3. 4.1.2 HRIG
  4. 4.2 Global Human Rabies Immunoglobulin (IM) Sales by Type
  5. 4.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Rabies Immunoglobulin (IM) Sales by Type (2021-2032)
  7. 4.2.3 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Human Rabies Immunoglobulin (IM) Revenue by Type
  9. 4.3.1 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2021-2032)
  11. 4.3.3 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Type (2021-2032)
5 Human Rabies Immunoglobulin (IM) Market by Application
  1. 5.1 Human Rabies Immunoglobulin (IM) Application Introduction
  2. 5.1.1 Category II Exposure
  3. 5.1.2 Category III Exposure
  4. 5.2 Global Human Rabies Immunoglobulin (IM) Sales by Application
  5. 5.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Rabies Immunoglobulin (IM) Sales by Application (2021-2032)
  7. 5.2.3 Global Human Rabies Immunoglobulin (IM) Sales Market Share by Application (2021-2032)
  8. 5.3 Global Human Rabies Immunoglobulin (IM) Revenue by Application
  9. 5.3.1 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2021-2032)
  11. 5.3.3 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Application (2021-2032)
6 Global Human Rabies Immunoglobulin (IM) Sales by Region
  1. 6.1 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Rabies Immunoglobulin (IM) Sales by Region (2021-2032)
  3. 6.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Region (2021-2026)
  4. 6.2.2 Global Human Rabies Immunoglobulin (IM) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Rabies Immunoglobulin (IM) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Human Rabies Immunoglobulin (IM) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Human Rabies Immunoglobulin (IM) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Human Rabies Immunoglobulin (IM) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Human Rabies Immunoglobulin (IM) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Human Rabies Immunoglobulin (IM) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Human Rabies Immunoglobulin (IM) Revenue by Region
  1. 7.1 Global Human Rabies Immunoglobulin (IM) Revenue by Region
  2. 7.1.1 Global Human Rabies Immunoglobulin (IM) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Human Rabies Immunoglobulin (IM) Revenue by Region (2021-2026)
  4. 7.1.3 Global Human Rabies Immunoglobulin (IM) Revenue by Region (2027-2032)
  5. 7.1.4 Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Human Rabies Immunoglobulin (IM) Revenue (2021-2032)
  8. 7.2.2 North America Human Rabies Immunoglobulin (IM) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Human Rabies Immunoglobulin (IM) Revenue (2021-2032)
  11. 7.3.2 Europe Human Rabies Immunoglobulin (IM) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Human Rabies Immunoglobulin (IM) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL Behring
  2. 8.1.1 CSL Behring Company Information
  3. 8.1.2 CSL Behring Business Overview
  4. 8.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
  6. 8.1.5 CSL Behring Recent Developments
  7. 8.2 Grifols
  8. 8.2.1 Grifols Company Information
  9. 8.2.2 Grifols Business Overview
  10. 8.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
  12. 8.2.5 Grifols Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Sichuan Yuanda Shuyang
  20. 8.4.1 Sichuan Yuanda Shuyang Company Information
  21. 8.4.2 Sichuan Yuanda Shuyang Business Overview
  22. 8.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
  24. 8.4.5 Sichuan Yuanda Shuyang Recent Developments
  25. 8.5 CNBG
  26. 8.5.1 CNBG Company Information
  27. 8.5.2 CNBG Business Overview
  28. 8.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
  30. 8.5.5 CNBG Recent Developments
  31. 8.6 Kamada
  32. 8.6.1 Kamada Company Information
  33. 8.6.2 Kamada Business Overview
  34. 8.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
  36. 8.6.5 Kamada Recent Developments
  37. 8.7 CBPO
  38. 8.7.1 CBPO Company Information
  39. 8.7.2 CBPO Business Overview
  40. 8.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
  42. 8.7.5 CBPO Recent Developments
  43. 8.8 Shuanglin Bio
  44. 8.8.1 Shuanglin Bio Company Information
  45. 8.8.2 Shuanglin Bio Business Overview
  46. 8.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
  48. 8.8.5 Shuanglin Bio Recent Developments
  49. 8.9 Weiguang Bio
  50. 8.9.1 Weiguang Bio Company Information
  51. 8.9.2 Weiguang Bio Business Overview
  52. 8.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
  54. 8.9.5 Weiguang Bio Recent Developments
  55. 8.10 Shanghai RAAS
  56. 8.10.1 Shanghai RAAS Company Information
  57. 8.10.2 Shanghai RAAS Business Overview
  58. 8.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
  60. 8.10.5 Shanghai RAAS Recent Developments
  61. 8.11 Bharat Serum
  62. 8.11.1 Bharat Serum Company Information
  63. 8.11.2 Bharat Serum Business Overview
  64. 8.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
  66. 8.11.5 Bharat Serum Recent Developments
  67. 8.12 VINS
  68. 8.12.1 VINS Company Information
  69. 8.12.2 VINS Business Overview
  70. 8.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
  72. 8.12.5 VINS Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Rabies Immunoglobulin (IM) Value Chain Analysis
  2. 9.1.1 Human Rabies Immunoglobulin (IM) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Rabies Immunoglobulin (IM) Production Mode & Process
  6. 9.2 Human Rabies Immunoglobulin (IM) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Rabies Immunoglobulin (IM) Distributors
  9. 9.2.3 Human Rabies Immunoglobulin (IM) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst